541-02-6
CAS 541-02-6
541-02-6 (CAS 541-02-6) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 1000 nM | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| CYCLOPENTASILOXANE | 1305744 | SU | MTHSPL |
| CYCLOMETHICONE 5 | 1305744 | SU | MTHSPL |
| Cyclomethicone 5 | 1305744 | SU | MTHSPL |
| cyclomethicone 5 | 1305744 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 541-02-6 used for in pharmaceutical contexts?
541-02-6 (CAS 541-02-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 541-02-6?
No adverse-event association or SIDER side-effect rows are rendered for 541-02-6 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 541-02-6 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Cyclomethicone with EU status "restricted".
What clinical phase is 541-02-6 in?
No phase 1-4 clinical development badge is rendered for 541-02-6 because the matched compound identifier rows do not contain a max-phase value.